-
Product Insights
Ewing Sarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Ewing Sarcoma - Drugs In Development, 2023’, provides an overview of the Ewing Sarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ewing Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Sector Analysis
United States (US) Thermal Power Market Analysis by Size, Installed Capacity, Power Generation, Regulations, Key Players and Forecast to 2035
United States (US) Thermal Power Market Report Overview The cumulative capacity for thermal power in the US was 808.9 GW in 2022. It is expected to achieve a negative CAGR of less than 1% during 2022-2035. The US thermal power market research report highlights installed capacity and power generation trends from 2010 to 2035. The report discusses the key insights about the major active and upcoming thermal power plants in the US. US Thermal Power Market Outlook, 2022-2035 (GW) Buy...
-
Product Insights
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Drugs In Development, 2023’, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Neuroblastoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroblastoma - Drugs In Development, 2023’, provides an overview of the Neuroblastoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XmAb-808 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. XmAb-808 in Solid Tumor Drug Details: Xmab-808 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XmAb-808 in Epithelial Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. XmAb-808 in Epithelial Ovarian Cancer Drug Details: Xmab-808 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Metastatic Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Plogosertib in Metastatic Ovarian Cancer Drug Details: Plogosertib is under development for the treatment of...
-
Product Insights
Koolan Island Mine
The Koolan Island Mine is a iron ore mine in Australia. It is currently in operation. Empower your strategies with our Koolan Island Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ANX-009 in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ANX-009 in Lupus Nephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ANX-009 in Lupus Nephritis Drug Details:ANX-009 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KIN-3248 in Bile Duct Cancer (Cholangiocarcinoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KIN-3248 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: KIN-3248 is under development for the treatment...